Dolca Thomas, M.D.

Venture Partner, Board Member Allakos Therapeutics, Ventus Therapeutics

Dolca Thomas, M.D., is currently a venture partner at Samsara and serves on the Board of Directors of Allakos Therapeutics and Ventus Therapeutics. She was most recently the executive vice president, head of Research and Development and chief medical officer of Equillium from January 2021 until February 2022. She served as Principia’s chief medical officer from 2018 until the Sanofi acquisition in September 2020. Prior to Principia, Dr. Thomas was vice president and global head of Translational Medicine for Immunology, Inflammation, and Infectious Disease at Roche; vice president of Clinical Development and Clinical Immunophenotyping at Pfizer and vice president and chief development officer of the Biosimilars Research and Development Unit at Pfizer. She started her industry career as a director of Global Clinical Development in Immunology at BMS. Prior to her career in drug development, she was a faculty member at Weill Cornell Medicine’s Department of Nephrology and Transplantation Medicine and Director of the Islet Cell Transplantation Program. Dr. Thomas received a B.A. in sociology and a M.D. from Cornell University.